Nataliia Levchuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nataliia Levchuk has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Victor Volodymyrovich Pushkarev
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
24 shared publications - Olena Igorevna Kovzun
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
19 shared publications - Mykola Tronko
State Institution “V.P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
16 shared publications - Bogdan B. Guda
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
8 shared publications - Igor I. Komisarenko
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
8 shared publications - Nataliia Ya. Kobrynska
V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU, Kyiv, Ukraine
8 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 755-759
Expression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions
Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 755-759
Open AccessExpression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions
Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.
- Open Access
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 593-598
Inhibitor of nuclear factor kappa B expression in papillary thyroid carcinoma and benign neoplasms
Background. The eukaryotic transcription factor NF-κB regulates a variety of biological processes, particularly immune response and inflammatory processes. Dysregulation of NF-κB-dependent signaling mechanisms is associated with serious human diseases, including cancer, autoimmune diseases, and chronic inflammation. NF-κB inhibitor kappa B subunit beta (IκBβ) plays a key role in regulating NF-κB activity and is implicated in thyroid cancer, particularly in aggressive and metastatic forms. The aim of this study was to compare levels of IκBβ in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), and in blood plasma of PTC patients. Materials and methods. Postoperative samples of tissues, blood plasma were obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic. The amount of IκBβ was determined using enzyme immunoassay kits. Results. There were no significant differences between IκBβ levels in benign neoplasms and CN tissue. A minor difference was detected between CN tissue and PTC tissue without metastases. In PTC tissues with metastases, IκBβ levels were more than 1.5-fold lower than in CN tissue. The lowest IκBβ levels were detected in metastatic tissue. Рlasma IκBβ concentrations in PTC patients were significantly lower than in controls, with no differences between patients with and without metastases. Conclusions. IκBβ levels in benign thyroid neoplasms did not differ from CN tissue. In metastatic PTC tissues and especially in metastatic lesions, IκBβ concentrations were significantly reduced compared to CN tissue. Decreased IκBβ levels in primary tumors and metastatic lesions may indicate NF-κB activation and enhanced inflammatory signaling. Alterations in IκBβ expression may be useful for predicting metastatic potential in PTC, while plasma IκBβ levels could serve as a potential preoperative diagnostic biomarker.
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 593-598
Open AccessInhibitor of nuclear factor kappa B expression in papillary thyroid carcinoma and benign neoplasms
Background. The eukaryotic transcription factor NF-κB regulates a variety of biological processes, particularly immune response and inflammatory processes. Dysregulation of NF-κB-dependent signaling mechanisms is associated with serious human diseases, including cancer, autoimmune diseases, and chronic inflammation. NF-κB inhibitor kappa B subunit beta (IκBβ) plays a key role in regulating NF-κB activity and is implicated in thyroid cancer, particularly in aggressive and metastatic forms. The aim of this study was to compare levels of IκBβ in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), and in blood plasma of PTC patients. Materials and methods. Postoperative samples of tissues, blood plasma were obtained from the surgical department of the V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMSU clinic. The amount of IκBβ was determined using enzyme immunoassay kits. Results. There were no significant differences between IκBβ levels in benign neoplasms and CN tissue. A minor difference was detected between CN tissue and PTC tissue without metastases. In PTC tissues with metastases, IκBβ levels were more than 1.5-fold lower than in CN tissue. The lowest IκBβ levels were detected in metastatic tissue. Рlasma IκBβ concentrations in PTC patients were significantly lower than in controls, with no differences between patients with and without metastases. Conclusions. IκBβ levels in benign thyroid neoplasms did not differ from CN tissue. In metastatic PTC tissues and especially in metastatic lesions, IκBβ concentrations were significantly reduced compared to CN tissue. Decreased IκBβ levels in primary tumors and metastatic lesions may indicate NF-κB activation and enhanced inflammatory signaling. Alterations in IκBβ expression may be useful for predicting metastatic potential in PTC, while plasma IκBβ levels could serve as a potential preoperative diagnostic biomarker.
- Open Access
- 17 June 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (2) , 285-289
PATHOGENESIS OF DISTRESS AND COMBINED APPROACHES TO ITS CORRECTION
Contemporary conditions of societal development can be characterized by long-term crisis phenomena, global challenges, and high intensity of social changes, which contribute to the increasing number of patients with psychological distress (chronic stress). This condition not only reduces the quality of an individual’s life, but also creates a significant social burden, expressed in the loss of ability to work, increased costs of health care and social support. Consequently, the problem of timely diagnosis, classification and effective correction of distress becomes of great importance for both practical psychology, medicine and the social sciences in general. An analysis of recent studies published over the past 5–7 years demonstrates a shift in the scientific paradigm for understanding distress. Rather than being viewed as a simple response to stressors, distress is now interpreted as a multidimensional and integrative phenomenon encompassing neuroimmune-endocrine, metabolic, psychoemotional, cognitive, and socio-behavioral components. Contemporary neuroscience increasingly adopts a multidisciplinary perspective, considering distress as a dynamic system characterized by complex interactions among biological, psychological, and social factors. Despite significant progress in this area of knowledge, key aspects of the problem remain unresolved. In particular, classifications of distress, which take into account the wide range of its manifestations from early functional changes to the development of persistent pathological conditions, are insufficiently systematized. There is also an urgent need to evaluate the effectiveness of correction that would integrate biological (impact on the microbiome and others), psychological (cognitive-behavioral, body-oriented interventions), and social (humanitarian and financial assistance) approaches into unified rehabilitation programs for patients. By analogy with the surgical management of combat injuries, where effective recovery of wounded individuals is achievable only through early and comprehensive intervention, the importance of timely and integrated support becomes evident. In the absence of such intervention, the risk of consolidation of pathological changes and deterioration of treatment outcomes increases significantly. Thus, this review article provides current scientific evidence on the pathogenesis of psychological distress and substantiated interdisciplinary approaches to its correction.
- 17 June 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (2) , 285-289
Open AccessPATHOGENESIS OF DISTRESS AND COMBINED APPROACHES TO ITS CORRECTION
Contemporary conditions of societal development can be characterized by long-term crisis phenomena, global challenges, and high intensity of social changes, which contribute to the increasing number of patients with psychological distress (chronic stress). This condition not only reduces the quality of an individual’s life, but also creates a significant social burden, expressed in the loss of ability to work, increased costs of health care and social support. Consequently, the problem of timely diagnosis, classification and effective correction of distress becomes of great importance for both practical psychology, medicine and the social sciences in general. An analysis of recent studies published over the past 5–7 years demonstrates a shift in the scientific paradigm for understanding distress. Rather than being viewed as a simple response to stressors, distress is now interpreted as a multidimensional and integrative phenomenon encompassing neuroimmune-endocrine, metabolic, psychoemotional, cognitive, and socio-behavioral components. Contemporary neuroscience increasingly adopts a multidisciplinary perspective, considering distress as a dynamic system characterized by complex interactions among biological, psychological, and social factors. Despite significant progress in this area of knowledge, key aspects of the problem remain unresolved. In particular, classifications of distress, which take into account the wide range of its manifestations from early functional changes to the development of persistent pathological conditions, are insufficiently systematized. There is also an urgent need to evaluate the effectiveness of correction that would integrate biological (impact on the microbiome and others), psychological (cognitive-behavioral, body-oriented interventions), and social (humanitarian and financial assistance) approaches into unified rehabilitation programs for patients. By analogy with the surgical management of combat injuries, where effective recovery of wounded individuals is achievable only through early and comprehensive intervention, the importance of timely and integrated support becomes evident. In the absence of such intervention, the risk of consolidation of pathological changes and deterioration of treatment outcomes increases significantly. Thus, this review article provides current scientific evidence on the pathogenesis of psychological distress and substantiated interdisciplinary approaches to its correction.
- Open Access
- 17 June 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (4) , 447-453
Expression of EMT transcription factors Twist1 and Slug in benign and malignant thyroid tumors
Background. Papillary thyroid carcinoma (PTC) usually has a favorable prognosis; however, lymph node metastases, extrathyroidal extension, and radioiodine refractoriness significantly contribute to recurrence and reduced survival. Epithelial-mesenchymal transition (EMT) is a key mechanism driving invasive and metastatic behavior in PTC, yet its central transcriptional regulators remain incompletely defined. The purpose of the study was to compare the levels of the EMT-associated transcription factors Twist1 and Slug in histologically unchanged conditionally normal (CN) tissue, nodular goiter, PTC tissues, and metastases. Materials and methods. Western blotting was used to evaluate the expression of EMT transcription factors Twist1 and Slug (SNAI2) in tissues of nodular goiter, PTC and metastasis. Results. No differences in Slug expression were found between CN tissue and nodular goiter. A small but significant increase in Slug concentration was observed in PTC tissues without metastases. In PTC tissues with metastases, Slug expression in the primary tumor was more than 12-fold higher than in CN tissue and more than 4-fold higher than in PTC tissues without metastases. Extremely high levels of Slug were also detected in metastatic tissues. In PTC tissues with and without metastases, Twist1 expression was higher than in CN tissue. Conclusions. Current evidence identifies Twist1 and Slug as central regulators of EMT-driven invasion and metastases in PTC. Mechanistically, a Twist1/Slug-EMT-lymph node metastases axis underlies loss of epithelial differentiation, acquisition of invasive traits, and metastatic spread in PTC. Our data demonstrate significant differences in Slug concentration between PTC tissues with and without metastases. Slug expression in PTC tumor tissue with metastases may serve as a biomarker of metastatic potential and as a diagnostic marker for distinguishing benign from malignant thyroid neoplasms.
- 17 June 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (4) , 447-453
Open AccessExpression of EMT transcription factors Twist1 and Slug in benign and malignant thyroid tumors
Background. Papillary thyroid carcinoma (PTC) usually has a favorable prognosis; however, lymph node metastases, extrathyroidal extension, and radioiodine refractoriness significantly contribute to recurrence and reduced survival. Epithelial-mesenchymal transition (EMT) is a key mechanism driving invasive and metastatic behavior in PTC, yet its central transcriptional regulators remain incompletely defined. The purpose of the study was to compare the levels of the EMT-associated transcription factors Twist1 and Slug in histologically unchanged conditionally normal (CN) tissue, nodular goiter, PTC tissues, and metastases. Materials and methods. Western blotting was used to evaluate the expression of EMT transcription factors Twist1 and Slug (SNAI2) in tissues of nodular goiter, PTC and metastasis. Results. No differences in Slug expression were found between CN tissue and nodular goiter. A small but significant increase in Slug concentration was observed in PTC tissues without metastases. In PTC tissues with metastases, Slug expression in the primary tumor was more than 12-fold higher than in CN tissue and more than 4-fold higher than in PTC tissues without metastases. Extremely high levels of Slug were also detected in metastatic tissues. In PTC tissues with and without metastases, Twist1 expression was higher than in CN tissue. Conclusions. Current evidence identifies Twist1 and Slug as central regulators of EMT-driven invasion and metastases in PTC. Mechanistically, a Twist1/Slug-EMT-lymph node metastases axis underlies loss of epithelial differentiation, acquisition of invasive traits, and metastatic spread in PTC. Our data demonstrate significant differences in Slug concentration between PTC tissues with and without metastases. Slug expression in PTC tumor tissue with metastases may serve as a biomarker of metastatic potential and as a diagnostic marker for distinguishing benign from malignant thyroid neoplasms.
- Open Access
- 15 June 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (2) , 7-13
LEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS
Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases. Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA). Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases. Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.
- 15 June 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (2) , 7-13
Open AccessLEVEL OF MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN MEDULLARY AND PAPILLARY THYROID CARCINOMAS
Monocyte chemoattractant protein-1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a prototypical member of the C-C chemokine superfamily (MCP-1/2/3/4) that signals through G protein–coupled receptors to orchestrate leukocyte recruitment. By regulating the trafficking and activation of monocytes and basophils, MCP-1 critically modulates inflammatory responses. In the oncologic context, MCP-1 promotes tumor progression and metastatic dissemination through the recruitment of tumor-associated macrophages, thereby fostering a microenvironment conducive to cancer cell survival, migration, and invasion. This study aimed to comparatively evaluate MCP-1 levels in conditionally normal (CN) thyroid tissue, primary medullary thyroid carcinoma (MTC) tissues, and corresponding metastatic (Mts) lesions, as well as in blood plasma from patients with medullary thyroid carcinoma and papillary thyroid carcinoma (PTC) with and without metastases. Materials and methods. Postoperative thyroid tissue specimens and peripheral blood plasma were collected from patients undergoing surgical treatment. MCP-1 concentrations were quantified using enzyme-linked immunosorbent assay (ELISA). Results. MCP-1 expression was significantly elevated in primary MTC tissues without metastases compared with matched CN thyroid tissue. In metastatic MTC, tissue MCP-1 levels were increased more than threefold relative to corresponding normal tissue, with the highest expression observed in lymph node metastatic deposits. Consistently, circulating MCP-1 concentrations were significantly higher in patients with metastatic MTC than in those with non-metastatic disease. No significant difference in plasma MCP-1 concentration was found between metastatic РTC and РTC without metastases. Conclusions. MCP-1 expression is markedly upregulated in metastatic versus non-metastatic medullary thyroid carcinoma at both tissue and systemic levels. These findings implicate MCP-1 as a potential preoperative biomarker for stratifying metastatic risk in medullary thyroid carcinoma.
- Open Access
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 241-246
The role of vascular endothelial growth factor C in thyroid cancer metastasis
Background. The vascular endothelial growth factor (VEGF) system includes several ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and their receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A primarily signals through VEGFR-2, promoting endothelial cell proliferation, migration, and survival. VEGF-C and VEGF-D are particularly important for lymphangiogenesis via VEGFR-3, which is highly relevant to lymph node metastasis in thyroid cancer. The aim of this study was to compare levels of VEGF in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), as well as in blood plasma and peripheral blood mononuclear cells (PBMC) of patients with PTC. Materials and methods. Postoperative samples of tissue, blood plasma, and cells were obtained from the surgical department of the IEM clinic. The amount of VEGF was determined using enzyme immunoassay kits. Results. VEGF levels in benign neoplasms did not differ from those in CN tissue. There was significant difference between CN tissue and РТС tissues without Mts. The level of VEGF-C in the РТС tissues with Mts was ~ 2.5 times higher than in CN tissues. The high level of VEGF-C was observed in the Mts tissue. The VEGF-C concentration in PTC tissue with Mts exceeded its level in the PTC tissues without Mts by more than 2 times. In plasma and, especially, PBMC of PTC patients, VEGF-C concentration significantly exceeded control levels but there were no differences between specimens with and without Mts. Conclusions. VEGF-C levels in benign thyroid neoplasms did not differ from those in CN tissue. In PTC tissues with Mts, VEGF-C concentrations were significantly elevated compared to CN and PTC tissues without Mts. Our findings reveal significant differences in VEGF concentrations between PTC tissues with and without Mts, which may be useful for predicting metastatic potential of tumor. The level of VEGF-C in plasma and PBMC can become the basis for PTC diagnosis in the preoperative period.
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 241-246
Open AccessThe role of vascular endothelial growth factor C in thyroid cancer metastasis
Background. The vascular endothelial growth factor (VEGF) system includes several ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and their receptors: VEGFR-1, VEGFR-2, and VEGFR-3. VEGF-A primarily signals through VEGFR-2, promoting endothelial cell proliferation, migration, and survival. VEGF-C and VEGF-D are particularly important for lymphangiogenesis via VEGFR-3, which is highly relevant to lymph node metastasis in thyroid cancer. The aim of this study was to compare levels of VEGF in tissue samples of conditionally normal (CN) thyroid tissue, follicular adenoma, goiters, papillary thyroid carcinoma (PTC), metastasis (Mts), as well as in blood plasma and peripheral blood mononuclear cells (PBMC) of patients with PTC. Materials and methods. Postoperative samples of tissue, blood plasma, and cells were obtained from the surgical department of the IEM clinic. The amount of VEGF was determined using enzyme immunoassay kits. Results. VEGF levels in benign neoplasms did not differ from those in CN tissue. There was significant difference between CN tissue and РТС tissues without Mts. The level of VEGF-C in the РТС tissues with Mts was ~ 2.5 times higher than in CN tissues. The high level of VEGF-C was observed in the Mts tissue. The VEGF-C concentration in PTC tissue with Mts exceeded its level in the PTC tissues without Mts by more than 2 times. In plasma and, especially, PBMC of PTC patients, VEGF-C concentration significantly exceeded control levels but there were no differences between specimens with and without Mts. Conclusions. VEGF-C levels in benign thyroid neoplasms did not differ from those in CN tissue. In PTC tissues with Mts, VEGF-C concentrations were significantly elevated compared to CN and PTC tissues without Mts. Our findings reveal significant differences in VEGF concentrations between PTC tissues with and without Mts, which may be useful for predicting metastatic potential of tumor. The level of VEGF-C in plasma and PBMC can become the basis for PTC diagnosis in the preoperative period.
- Open Access
- 3 April 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (1) , 224-233
CLINICAL CHARACTERISTICS OF COMBAT-RELATED SOFT TISSUE INJURIES OF THE EXTREMITIES UNDET THE CONDITIONS OF CHRONIC STRESS
Modern military operations are characterized by an increasing number of patients with limb injuries, the treatment of which remains a complex medical challenge. The management of such injuries primarily relies on surgical approaches, particularly in cases of combat-related soft tissue damage. The present study focuses on primary and secondary surgical wound treatment. The combination of these methods with vacuum-assisted therapy and the assessment of granulation tissue formation demonstrates their effectiveness. An important aspect of the study is the analysis of factors contributing to severe purulent-inflammatory complications and repeated wound contamination by pathogenic microorganisms. These complications significantly worsen the clinical course, necessitate multiple surgical interventions, and are frequently associated with limb amputation, thereby adversely affecting patient outcomes. The presence of compartment syndrome and local hypertensive-ischemic syndrome further complicates wound management and worsens prognosis. Particular attention is also given to neuro–immune–endocrine dysfunctions that develop in the context of chronic psycho-emotional stress. These disturbances are further exacerbated by traumatic and surgical stress. The cumulative effect of these stressors necessitates not only surgical treatment and management of infectious complications but also continuous microbiological monitoring, as well as immunocorrective and pharmacological interventions aimed at restoring psycho-emotional and immuno-endocrine balance. These factors play a critical role in the progression and outcome of soft tissue injuries of the extremities in wounded servicemen.
- 3 April 2026
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 26 (1) , 224-233
Open AccessCLINICAL CHARACTERISTICS OF COMBAT-RELATED SOFT TISSUE INJURIES OF THE EXTREMITIES UNDET THE CONDITIONS OF CHRONIC STRESS
Modern military operations are characterized by an increasing number of patients with limb injuries, the treatment of which remains a complex medical challenge. The management of such injuries primarily relies on surgical approaches, particularly in cases of combat-related soft tissue damage. The present study focuses on primary and secondary surgical wound treatment. The combination of these methods with vacuum-assisted therapy and the assessment of granulation tissue formation demonstrates their effectiveness. An important aspect of the study is the analysis of factors contributing to severe purulent-inflammatory complications and repeated wound contamination by pathogenic microorganisms. These complications significantly worsen the clinical course, necessitate multiple surgical interventions, and are frequently associated with limb amputation, thereby adversely affecting patient outcomes. The presence of compartment syndrome and local hypertensive-ischemic syndrome further complicates wound management and worsens prognosis. Particular attention is also given to neuro–immune–endocrine dysfunctions that develop in the context of chronic psycho-emotional stress. These disturbances are further exacerbated by traumatic and surgical stress. The cumulative effect of these stressors necessitates not only surgical treatment and management of infectious complications but also continuous microbiological monitoring, as well as immunocorrective and pharmacological interventions aimed at restoring psycho-emotional and immuno-endocrine balance. These factors play a critical role in the progression and outcome of soft tissue injuries of the extremities in wounded servicemen.
- Open Access
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 135-139
Fibroblast growth factor 19 level in blood plasma, thyroid tumors and metastasis
Background. The endocrine subfamily of fibroblast growth factor 19 (FGF19) consists of FGF19, FGF21, and FGF23. Numerous data indicate that FGF19 is involved in carcinogenesis, epithelial-mesenchymal transition, metastasis formation, and tumor resistance to inhibitors. The purpose of the study was to compare the levels of FGF19 in tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma (PTC), metastasis (Mts), and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the IEM clinic, were used for research. The amount of FGF19 was determined using enzyme immunoassay kits. Results. The level of FGF19 in the tissue of follicular adenoma and goiter exceeded the levels in conditionally normal tissue. There was also significant difference between normal tissue and РТС tissues with and without Mts. It is important to note that the level of FGF19 in metastasis was higher than in the tumor tissue of the РТС. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 significantly exceeded its level in control plasma and in the blood of patients with PTC without Mts. In plasma of patients with PTC without Mts, the concentration of the FGF19 did not differ from its concentration in blood of healthy people. Conclusions. Our data indicate significant differences in the concentration of FGF19 between tumor tissues of PTC and Mts. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 exceeded its level in control plasma and the concentration of FGF19 in the blood of patients with PTC without Mts. There was no difference between level of FGF19 in the blood of patients with PTC without Mts and in control plasma. The latter facts may be useful for predicting the formation of Mts.
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 135-139
Open AccessFibroblast growth factor 19 level in blood plasma, thyroid tumors and metastasis
Background. The endocrine subfamily of fibroblast growth factor 19 (FGF19) consists of FGF19, FGF21, and FGF23. Numerous data indicate that FGF19 is involved in carcinogenesis, epithelial-mesenchymal transition, metastasis formation, and tumor resistance to inhibitors. The purpose of the study was to compare the levels of FGF19 in tissue samples of follicular adenoma, goiter, papillary thyroid carcinoma (PTC), metastasis (Mts), and conditionally normal tissue. Materials and methods. Postoperative samples of tissue and blood plasma, obtained from the surgical department of the IEM clinic, were used for research. The amount of FGF19 was determined using enzyme immunoassay kits. Results. The level of FGF19 in the tissue of follicular adenoma and goiter exceeded the levels in conditionally normal tissue. There was also significant difference between normal tissue and РТС tissues with and without Mts. It is important to note that the level of FGF19 in metastasis was higher than in the tumor tissue of the РТС. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 significantly exceeded its level in control plasma and in the blood of patients with PTC without Mts. In plasma of patients with PTC without Mts, the concentration of the FGF19 did not differ from its concentration in blood of healthy people. Conclusions. Our data indicate significant differences in the concentration of FGF19 between tumor tissues of PTC and Mts. In blood plasma of patients with PTC and Mts, the concentration of the FGF19 exceeded its level in control plasma and the concentration of FGF19 in the blood of patients with PTC without Mts. There was no difference between level of FGF19 in the blood of patients with PTC without Mts and in control plasma. The latter facts may be useful for predicting the formation of Mts.
- Open Access
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 7-13
DETERMINATION OF SURVIVIN AND PROTEIN KINASE AKT IN PAPILLARY THYROID CARCINOMA AND METASTASIS TISSUES
Background. Survivin is a member of Inhibitors of Apoptosis proteins (IAP) family. It is expressed in actively proliferating cells, and is upregulated in most cancers; consequently, it has received significant attention as a potential oncotherapeutic target. Akt is a central signalling molecule of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway. It is a serine/threonine-specific protein kinase and involved in apoptosis, proliferation, transcription and migration. Aberrant activation of this pathway has been identified in a wide range of cancers and thyroid as well. The aim of the study was to compare the expression of survivin and activation of protein kinase Akt in the tissues of patients with goiter, multinodular goiter (MNG), papillary thyroid carcinoma (PTC) with and without metastasis (Mts) to the lymph nodes. Materials and methods. Postoperative specimens of tumor tissue, metastasis (Mts), benign neoplasms (goiters) and conditionally normal tissue were used for the studies. The expression of survivin mRNA was determined using real-time polymerase chain reaction (qPCR). The expression of Akt was determined using Western-blotting. Results. The obtained data indicate that the expression of the survivin mRNA in PTC tissue and Mts significantly exceeds the level of its expression in conditionally normal (more than 4.5 times) and goiter tissues. The expression of survivin in PTC without metastasis more than three times lower compared to PTC with metastasis. In metastasis the level of IAP mRNA expression is lower than in the primary tumor. The expression of the phosphorylated (activated) form of Akt in PTC tissue and Mts significantly higher than level of its expression in conditionally normal tissue. The level of Akt in Mts is almost 4 times higher than in the primary tumor and almost 8 times higher than in the conditionally normal tissue. Сonclusions. Thus, an increased survivin mRNA expression in papillary thyroid carcinoma may be marker of metastasis formation. It can also be used to differentiate between benign and malignant thyroid lesions. The level of the phosphorylated (activated) form of Akt is especially high in metastasis.
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 7-13
Open AccessDETERMINATION OF SURVIVIN AND PROTEIN KINASE AKT IN PAPILLARY THYROID CARCINOMA AND METASTASIS TISSUES
Background. Survivin is a member of Inhibitors of Apoptosis proteins (IAP) family. It is expressed in actively proliferating cells, and is upregulated in most cancers; consequently, it has received significant attention as a potential oncotherapeutic target. Akt is a central signalling molecule of the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway. It is a serine/threonine-specific protein kinase and involved in apoptosis, proliferation, transcription and migration. Aberrant activation of this pathway has been identified in a wide range of cancers and thyroid as well. The aim of the study was to compare the expression of survivin and activation of protein kinase Akt in the tissues of patients with goiter, multinodular goiter (MNG), papillary thyroid carcinoma (PTC) with and without metastasis (Mts) to the lymph nodes. Materials and methods. Postoperative specimens of tumor tissue, metastasis (Mts), benign neoplasms (goiters) and conditionally normal tissue were used for the studies. The expression of survivin mRNA was determined using real-time polymerase chain reaction (qPCR). The expression of Akt was determined using Western-blotting. Results. The obtained data indicate that the expression of the survivin mRNA in PTC tissue and Mts significantly exceeds the level of its expression in conditionally normal (more than 4.5 times) and goiter tissues. The expression of survivin in PTC without metastasis more than three times lower compared to PTC with metastasis. In metastasis the level of IAP mRNA expression is lower than in the primary tumor. The expression of the phosphorylated (activated) form of Akt in PTC tissue and Mts significantly higher than level of its expression in conditionally normal tissue. The level of Akt in Mts is almost 4 times higher than in the primary tumor and almost 8 times higher than in the conditionally normal tissue. Сonclusions. Thus, an increased survivin mRNA expression in papillary thyroid carcinoma may be marker of metastasis formation. It can also be used to differentiate between benign and malignant thyroid lesions. The level of the phosphorylated (activated) form of Akt is especially high in metastasis.
- Open Access
- 28 February 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (1) , 11-14
ZEB1 level in thyroid papillary carcinoma tissue, metastasis, blood mononuclear cells and plasma
Background. Epithelial-mesenchymal transition (EMT) is a key process in the dissemination of tumor cells. Zinc finger E-box-binding homeobox 1 (ZEB1) is a central transcriptional regulator of EMT, a cellular program that underlies tumor invasion, metastatic dissemination, and therapeutic resistance. Evidence indicates that aberrant activation of ZEB1 promotes epithelial plasticity, invasive behavior, and metastatic competence of thyroid cancer cells. The purpose of the study was to compare the expression of ZEB1 in conditionally normal thyroid tissue, benign neoplasms, tumor tissue of papillary thyroid carcinoma (PTC) and metastasis, as well as in cells and blood plasma of patients with PTC. Materials and methods. Blood plasma, mononuclear cells, postoperative samples of tumor tissue, metastasis, and conditionally normal tissue were obtained from the surgical department of the Institute’s clinic. The ZEB1 concentration was determined using enzyme immunoassay kits. Statistical analysis and data presentation were performed using Origin 2019b software. Results. The amount of ZEB1 in tumor tissue exceeds its concentration in conditionally normal (histologically unchanged) tissue by more than 5 times. Approximately the same ratio in the amount of ZEB1 between normal and tumor tissues is observed in samples from patients with РТС and metastasis. The concentration of transcription factors in metastasis exceeds the norm by almost 10 times. The amount of ZEB1 in goiter tissue does not differ from conditionally normal tissue of РТС patients but it was significantly different from tumor tissue of carcinoma. Conclusions. Our data indicate significant differences in ZEB1 concentration between conditionally normal and tumor thyroid tissues. The level of ZEB1 in metastasis was even higher. It should be emphasized that both in blood cells and plasma of metastatic PТC patients, the level of ZEB1 was significantly higher than in healthy people and individuals with PТC without metastasis. The latter circumstance can become the basis for the preoperative prognosis of the development of metastasis in PTC patients.
- 28 February 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (1) , 11-14
Open AccessZEB1 level in thyroid papillary carcinoma tissue, metastasis, blood mononuclear cells and plasma
Background. Epithelial-mesenchymal transition (EMT) is a key process in the dissemination of tumor cells. Zinc finger E-box-binding homeobox 1 (ZEB1) is a central transcriptional regulator of EMT, a cellular program that underlies tumor invasion, metastatic dissemination, and therapeutic resistance. Evidence indicates that aberrant activation of ZEB1 promotes epithelial plasticity, invasive behavior, and metastatic competence of thyroid cancer cells. The purpose of the study was to compare the expression of ZEB1 in conditionally normal thyroid tissue, benign neoplasms, tumor tissue of papillary thyroid carcinoma (PTC) and metastasis, as well as in cells and blood plasma of patients with PTC. Materials and methods. Blood plasma, mononuclear cells, postoperative samples of tumor tissue, metastasis, and conditionally normal tissue were obtained from the surgical department of the Institute’s clinic. The ZEB1 concentration was determined using enzyme immunoassay kits. Statistical analysis and data presentation were performed using Origin 2019b software. Results. The amount of ZEB1 in tumor tissue exceeds its concentration in conditionally normal (histologically unchanged) tissue by more than 5 times. Approximately the same ratio in the amount of ZEB1 between normal and tumor tissues is observed in samples from patients with РТС and metastasis. The concentration of transcription factors in metastasis exceeds the norm by almost 10 times. The amount of ZEB1 in goiter tissue does not differ from conditionally normal tissue of РТС patients but it was significantly different from tumor tissue of carcinoma. Conclusions. Our data indicate significant differences in ZEB1 concentration between conditionally normal and tumor thyroid tissues. The level of ZEB1 in metastasis was even higher. It should be emphasized that both in blood cells and plasma of metastatic PТC patients, the level of ZEB1 was significantly higher than in healthy people and individuals with PТC without metastasis. The latter circumstance can become the basis for the preoperative prognosis of the development of metastasis in PTC patients.